Your self-paid drug costs now count toward insurance limits—faster coverage, lower bills

What it does

This bill requires health insurance plans to count out-of-pocket drug purchases toward a patient's deductible and out-of-pocket maximum, even when the patient chooses to pay cash instead of using their insurance benefits. It amends three federal health laws (the Public Health Service Act, ERISA, and the Internal Revenue Code) to apply this rule uniformly across group and individual health plans, effective January 1, 2027.

Why we flagged it

The bill's operative mechanism is a patient-protective rule that counts self-paid drug costs toward insurance limits, accelerating coverage and reducing total out-of-pocket burden. It is not a deregulation, subsidy, or industry carve-out—it is a consumer-facing cost-control mandate on insurers.

What the text implies

• Conforming amendments to Medicaid 'best price' and 'average manufacturer price' rules may reduce the rebates manufacturers owe to Medicaid when patients self-pay at lower prices, potentially shifting costs to the Medicaid program.
• Patients may face incentives to self-pay for drugs if out-of-pocket prices are lower than copays, which could reduce insurance claims volume and alter drug utilization patterns.
• Plans may respond by raising copays or narrowing formularies to offset the faster deductible/OOP accumulation, partially offsetting the patient benefit.
• The rule applies uniformly across group and individual markets, but individual-market plans may adjust premiums upward to account for faster OOP-maximum hits.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Patients who choose to pay cash for drugs (often to avoid formulary restrictions or prior authorization delays) now get credit toward their deductible and out-of-pocket maximum, reducing their total annual out-of-pocket spending and accelerating access to full insurance coverage. This closes a gap where self-pay spending was previously invisible to the insurance system.

Who stands to gain

• patients who self-pay for drugs
• patients with high-deductible plans who reach coverage sooner

Named in the bill

Public Health Service Act (Title XXVII, Part D), Employee Retirement Income Security Act of 1974 (ERISA), Internal Revenue Code of 1986, Social Security Act (Medicaid), group health plans, health insurance issuers, pharmaceutical manufacturers

Where it stands

7 cosponsors: 7 Republicans.

• Apr 14, 2026 — Introduced · Congress.gov: “Introduced in House”
• Apr 14, 2026 — Referred to House Committee on Ways and Means and House Committee on Education and Workforce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

3 lobbying clients named this bill on 3 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $96,189 in lobbying spend. A filing names 11 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 61% of bills with at least one filing.

Gregory Murphy, the sponsor, reported $1,068,698 in PAC receipts in the 2026 cycle.

• National Multiple Sclerosis Society — $66,189 on 1 filing
• Council for Affordable Health Coverage — $30,000 on 1 filing
• Chronic Care Policy Alliance — $0 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.